The association of circulating adiponectin levels with pancreatic cancer risk; a study within the prospective EPIC cohort

Verena A Grote; Sabine Rohrmann; Alexandra Nieters; Laure Dossus; Jytte Halkjaer; Anne Tjønneland; Kim Overvad; Jakob Stegger; Nathalie Chabbert-Buffet; Marie-Christine Boutron-Ruault; Françoise Clavel-Chapelon; Birgit Teucher; Susen Becker; Jukka Montonen; Heiner Boeing; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Domenico Palli; Sabina Sieri; Rosario Tumino; Paolo Vineis; Amalia Mattiello; Marcial Argüelles; Eric J Duell; Esther Molina-Montes; Nerea Larrañaga; María-Dolores Chirlaque; Aurelio Barricarte Gurrea; Suzanne M Jeurnink; Petra Hm Peeters; Weimin Ye; Malin Sund; Björn Lindkvist; Dorthe Johansen; Kay-Tee Khaw; Nick Wareham; Francesca L Crowe; Isabelle Romieu; Sabina Rinaldi; Mazda Jenab; Dora Romaguera; Dominique S Michaud; Elio Riboli; H Bas Bueno-de-Mesquita; Rudolf Kaaks

doi:10.1002/ijc.26244

The association of circulating adiponectin levels with pancreatic cancer risk; a study within the prospective EPIC cohort

Verena A Grote, Sabine Rohrmann, Alexandra Nieters, Laure Dossus, Jytte Halkjaer, Anne Tjønneland, Kim Overvad, Jakob Stegger, Nathalie Chabbert-Buffet, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon, Birgit Teucher, Susen Becker, Jukka Montonen, Heiner Boeing, Antonia Trichopoulou, Pagona Lagiou, Dimitrios Trichopoulos, Domenico Palli, Sabina SieriRosario Tumino, Paolo Vineis, Amalia Mattiello, Marcial Argüelles, Eric J Duell, Esther Molina-Montes, Nerea Larrañaga, María-Dolores Chirlaque, Aurelio Barricarte Gurrea, Suzanne M Jeurnink, Petra Hm Peeters, Weimin Ye, Malin Sund, Björn Lindkvist, Dorthe Johansen, Kay-Tee Khaw, Nick Wareham, Francesca L Crowe, Isabelle Romieu, Sabina Rinaldi, Mazda Jenab, Dora Romaguera, Dominique S Michaud, Elio Riboli, H Bas Bueno-de-Mesquita, Rudolf Kaaks

Research output: Contribution to journal › Journal article › Research › peer-review

41 Citations (Scopus)

Abstract

Excess body weight and type 2 diabetes mellitus, risk factors of pancreatic cancer, are characterized by decreased levels of adiponectin. In addition to anti-inflammatory and anti-proliferative actions, adiponectin has an important role in regulating glucose metabolism, i.e. decreasing circulating blood glucose levels. Prospectively, hyperglycemia has been associated with risk of pancreatic cancer. The aim of this study was to investigate the association of pre-diagnostic adiponectin levels with pancreatic cancer risk. We conducted a case-control study nested within EPIC. Blood samples of 452 pancreatic cancer cases and 452 individually matched controls were analyzed by immunoassays. Multivariate conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Overall, adiponectin showed no association with pancreas cancer risk; however, among never smokers, higher circulating levels of adiponectin were associated with a reduction in pancreatic cancer risk (OR = 0.44 [95% CI 0.23-0.82] for highest vs. lowest quartile), whereas among current smokers there was no significant association (OR = 1.59 [95% CI 0.67-3.76] for highest vs. lowest quartile; p-trend = 0.530; p-interaction = 0.309). In our study, lower adiponectin concentrations may be associated with the development of pancreatic cancer among never smokers, whereas the only other prospective study being conducted so far showed a decrease in risk among male smokers. Therefore, further studies are needed to clarify the role of adiponectin in pancreatic cancer development. © 2011 Wiley-Liss, Inc.

Original language	English
Journal	International Journal of Cancer
Volume	130
Pages (from-to)	2428-2437
ISSN	0020-7136
DOIs	https://doi.org/10.1002/ijc.26244
Publication status	Published - 2012
Externally published	Yes

Bibliographical note

Access to Document

10.1002/ijc.26244

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Grote, V. A., Rohrmann, S., Nieters, A., Dossus, L., Halkjaer, J., Tjønneland, A., Overvad, K., Stegger, J., Chabbert-Buffet, N., Boutron-Ruault, M-C., Clavel-Chapelon, F., Teucher, B., Becker, S., Montonen, J., Boeing, H., Trichopoulou, A., Lagiou, P., Trichopoulos, D., Palli, D., ... Kaaks, R. (2012). The association of circulating adiponectin levels with pancreatic cancer risk; a study within the prospective EPIC cohort. International Journal of Cancer, 130, 2428-2437. https://doi.org/10.1002/ijc.26244

@article{7af6c48a90504891915536adb2e0625e,

title = "The association of circulating adiponectin levels with pancreatic cancer risk; a study within the prospective EPIC cohort",

abstract = "Excess body weight and type 2 diabetes mellitus, risk factors of pancreatic cancer, are characterized by decreased levels of adiponectin. In addition to anti-inflammatory and anti-proliferative actions, adiponectin has an important role in regulating glucose metabolism, i.e. decreasing circulating blood glucose levels. Prospectively, hyperglycemia has been associated with risk of pancreatic cancer. The aim of this study was to investigate the association of pre-diagnostic adiponectin levels with pancreatic cancer risk. We conducted a case-control study nested within EPIC. Blood samples of 452 pancreatic cancer cases and 452 individually matched controls were analyzed by immunoassays. Multivariate conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Overall, adiponectin showed no association with pancreas cancer risk; however, among never smokers, higher circulating levels of adiponectin were associated with a reduction in pancreatic cancer risk (OR = 0.44 [95% CI 0.23-0.82] for highest vs. lowest quartile), whereas among current smokers there was no significant association (OR = 1.59 [95% CI 0.67-3.76] for highest vs. lowest quartile; p-trend = 0.530; p-interaction = 0.309). In our study, lower adiponectin concentrations may be associated with the development of pancreatic cancer among never smokers, whereas the only other prospective study being conducted so far showed a decrease in risk among male smokers. Therefore, further studies are needed to clarify the role of adiponectin in pancreatic cancer development. {\textcopyright} 2011 Wiley-Liss, Inc.",

author = "Grote, {Verena A} and Sabine Rohrmann and Alexandra Nieters and Laure Dossus and Jytte Halkjaer and Anne Tj{\o}nneland and Kim Overvad and Jakob Stegger and Nathalie Chabbert-Buffet and Marie-Christine Boutron-Ruault and Fran{\c c}oise Clavel-Chapelon and Birgit Teucher and Susen Becker and Jukka Montonen and Heiner Boeing and Antonia Trichopoulou and Pagona Lagiou and Dimitrios Trichopoulos and Domenico Palli and Sabina Sieri and Rosario Tumino and Paolo Vineis and Amalia Mattiello and Marcial Arg{\"u}elles and Duell, {Eric J} and Esther Molina-Montes and Nerea Larra{\~n}aga and Mar{\'i}a-Dolores Chirlaque and Gurrea, {Aurelio Barricarte} and Jeurnink, {Suzanne M} and Peeters, {Petra Hm} and Weimin Ye and Malin Sund and Bj{\"o}rn Lindkvist and Dorthe Johansen and Kay-Tee Khaw and Nick Wareham and Crowe, {Francesca L} and Isabelle Romieu and Sabina Rinaldi and Mazda Jenab and Dora Romaguera and Michaud, {Dominique S} and Elio Riboli and Bueno-de-Mesquita, {H Bas} and Rudolf Kaaks",

note = "Copyright {\textcopyright} 2011 Wiley-Liss, Inc.",

year = "2012",

doi = "10.1002/ijc.26244",

language = "English",

volume = "130",

pages = "2428--2437",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "Wiley",

}

Grote, VA, Rohrmann, S, Nieters, A, Dossus, L, Halkjaer, J, Tjønneland, A, Overvad, K, Stegger, J, Chabbert-Buffet, N, Boutron-Ruault, M-C, Clavel-Chapelon, F, Teucher, B, Becker, S, Montonen, J, Boeing, H, Trichopoulou, A, Lagiou, P, Trichopoulos, D, Palli, D, Sieri, S, Tumino, R, Vineis, P, Mattiello, A, Argüelles, M, Duell, EJ, Molina-Montes, E, Larrañaga, N, Chirlaque, M-D, Gurrea, AB, Jeurnink, SM, Peeters, PH, Ye, W, Sund, M, Lindkvist, B, Johansen, D, Khaw, K-T, Wareham, N, Crowe, FL, Romieu, I, Rinaldi, S, Jenab, M, Romaguera, D, Michaud, DS, Riboli, E, Bueno-de-Mesquita, HB & Kaaks, R 2012, 'The association of circulating adiponectin levels with pancreatic cancer risk; a study within the prospective EPIC cohort', International Journal of Cancer, vol. 130, pp. 2428-2437. https://doi.org/10.1002/ijc.26244

TY - JOUR

T1 - The association of circulating adiponectin levels with pancreatic cancer risk; a study within the prospective EPIC cohort

AU - Grote, Verena A

AU - Rohrmann, Sabine

AU - Nieters, Alexandra

AU - Dossus, Laure

AU - Halkjaer, Jytte

AU - Tjønneland, Anne

AU - Overvad, Kim

AU - Stegger, Jakob

AU - Chabbert-Buffet, Nathalie

AU - Boutron-Ruault, Marie-Christine

AU - Clavel-Chapelon, Françoise

AU - Teucher, Birgit

AU - Becker, Susen

AU - Montonen, Jukka

AU - Boeing, Heiner

AU - Trichopoulou, Antonia

AU - Lagiou, Pagona

AU - Trichopoulos, Dimitrios

AU - Palli, Domenico

AU - Sieri, Sabina

AU - Tumino, Rosario

AU - Vineis, Paolo

AU - Mattiello, Amalia

AU - Argüelles, Marcial

AU - Duell, Eric J

AU - Molina-Montes, Esther

AU - Larrañaga, Nerea

AU - Chirlaque, María-Dolores

AU - Gurrea, Aurelio Barricarte

AU - Jeurnink, Suzanne M

AU - Peeters, Petra Hm

AU - Ye, Weimin

AU - Sund, Malin

AU - Lindkvist, Björn

AU - Johansen, Dorthe

AU - Khaw, Kay-Tee

AU - Wareham, Nick

AU - Crowe, Francesca L

AU - Romieu, Isabelle

AU - Rinaldi, Sabina

AU - Jenab, Mazda

AU - Romaguera, Dora

AU - Michaud, Dominique S

AU - Riboli, Elio

AU - Bueno-de-Mesquita, H Bas

AU - Kaaks, Rudolf

PY - 2012

Y1 - 2012

N2 - Excess body weight and type 2 diabetes mellitus, risk factors of pancreatic cancer, are characterized by decreased levels of adiponectin. In addition to anti-inflammatory and anti-proliferative actions, adiponectin has an important role in regulating glucose metabolism, i.e. decreasing circulating blood glucose levels. Prospectively, hyperglycemia has been associated with risk of pancreatic cancer. The aim of this study was to investigate the association of pre-diagnostic adiponectin levels with pancreatic cancer risk. We conducted a case-control study nested within EPIC. Blood samples of 452 pancreatic cancer cases and 452 individually matched controls were analyzed by immunoassays. Multivariate conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Overall, adiponectin showed no association with pancreas cancer risk; however, among never smokers, higher circulating levels of adiponectin were associated with a reduction in pancreatic cancer risk (OR = 0.44 [95% CI 0.23-0.82] for highest vs. lowest quartile), whereas among current smokers there was no significant association (OR = 1.59 [95% CI 0.67-3.76] for highest vs. lowest quartile; p-trend = 0.530; p-interaction = 0.309). In our study, lower adiponectin concentrations may be associated with the development of pancreatic cancer among never smokers, whereas the only other prospective study being conducted so far showed a decrease in risk among male smokers. Therefore, further studies are needed to clarify the role of adiponectin in pancreatic cancer development. © 2011 Wiley-Liss, Inc.

AB - Excess body weight and type 2 diabetes mellitus, risk factors of pancreatic cancer, are characterized by decreased levels of adiponectin. In addition to anti-inflammatory and anti-proliferative actions, adiponectin has an important role in regulating glucose metabolism, i.e. decreasing circulating blood glucose levels. Prospectively, hyperglycemia has been associated with risk of pancreatic cancer. The aim of this study was to investigate the association of pre-diagnostic adiponectin levels with pancreatic cancer risk. We conducted a case-control study nested within EPIC. Blood samples of 452 pancreatic cancer cases and 452 individually matched controls were analyzed by immunoassays. Multivariate conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Overall, adiponectin showed no association with pancreas cancer risk; however, among never smokers, higher circulating levels of adiponectin were associated with a reduction in pancreatic cancer risk (OR = 0.44 [95% CI 0.23-0.82] for highest vs. lowest quartile), whereas among current smokers there was no significant association (OR = 1.59 [95% CI 0.67-3.76] for highest vs. lowest quartile; p-trend = 0.530; p-interaction = 0.309). In our study, lower adiponectin concentrations may be associated with the development of pancreatic cancer among never smokers, whereas the only other prospective study being conducted so far showed a decrease in risk among male smokers. Therefore, further studies are needed to clarify the role of adiponectin in pancreatic cancer development. © 2011 Wiley-Liss, Inc.

U2 - 10.1002/ijc.26244

DO - 10.1002/ijc.26244

M3 - Journal article

SN - 0020-7136

VL - 130

SP - 2428

EP - 2437

JO - International Journal of Cancer

JF - International Journal of Cancer

ER -

The association of circulating adiponectin levels with pancreatic cancer risk; a study within the prospective EPIC cohort

Abstract

Bibliographical note

Access to Document

AUB Link

Fingerprint

Cite this